TABLE 3.

Co‐morbidities, therapy administered and outcomes of the population on admission

	Total (N = 175)	DM (n = 64, 36.6%)	Non DM (n = 111, 63.4%)	p Value
Co‐morbidities
Hypertension	97 (55.4%)	55 (85.9%)	42 (37.8%)	<.0001
Infectious diseases	21 (12.1%)	7 (10.1%)	14 (12.8%)	.98
Pulmonary diseases	7 (4.1%)	3 (4.7%)	4 (3.7%)
Renal diseases	12 (6.94%)	6 (9.4%)	6 (5.5%)
Neurological diseases	10 (5.8%)	4 (6.3%)	6 (5.5%)
Gastrointestinal disease	10 (5.8%)	2 (3.1%)	8 (7.3%)
Genitourinary disease	2 (1.2%)	1 (1.6%)	1 (0.9%)
Cardiovascular disease	18 (10.4%)	8 (12.5%)	10 (9.2%)
Others	7 (4.1%)	3 (4.7%)	4 (3.7%)
Hepatitis B positive (n = 99)	9 (9.1%)	3 (8.8%)	6 (9.2%)	1.00
Hepatitis C antibodies (n = 83)	2 (2.4%)	0 (0%)	2 (3.9%)	.52
HIV antibodies (n = 107)	11 (10.3%)	0 (0%)	11 (15.7%)	.015
Therapy administered
Hydroxychloroquine	85 (48.6%)	28 (43.8%)	57 (51.4%)	.33
Azithromycin	139 (79.4%)	53 (82.8%)	86 (77.5%)	.40
Zinc/Vit C	95 (54.3%)	32 (40.5%)	65 (67.7%)	.11
Zinc/Vit C/dexamethasone	71 (40.6%)	43 (54.4%)	28 (29.2%)
Zinc/Vit C/dexamethasone/tocilizumab	5 (2.9%)	4 (5.1%)	1 (1.0%)
Anti – diabetic agents on admission (n = 174)
Oral antiglycaemics only	27 (15.5%)	27 (42.9%)	0 (0%)	<.0001
Oral antiglycaemics and insulin	23 (13.2%)	23 (36.5%)	0 (0%)
Insulin only	3 (1.7%)	3 (4.8%)	0 (0%)
Oxygen needed during admission	112 (64%)	45 (70.3%)	67 (60.4%)	.19
Ventilatory support
Non invasive (CPAP)	9 (5.1%)	5 (7.8%)	4 (3.6%)	.26
Invasive	5 (2.9%)	3 (4.7%)	2 (1.8%)
Dialysis	5 (2.9%)	2 (3.1%)	3 (2.7%)	1.00
Outcome
Hospital transfer	20 (11.4%)	9 (14.1%)	11 (9.9%)	.61
Home	97 (55.4%)	36 (56.3%)	61 (54.9%)
Death	58 (33.1%)	19 (29.7%)	39 (35.1%)

Note: Others – Skin, Endocrine, Rheumatological and Haematological diseases.

Abbreviations: CPAP, continuous positive airway pressure; Vit C, Vitamin C.